Sucampo Ag

R-tech Ueno, Ltd.

K.k. Ueno Seiyaku Oyo Kenkyujo

Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

Vlp Therapeutics, LLC

Research Development Corporation of Japan

Ueno Seiyaku Kabushikikaisha

Sucampo Ag (usa) Inc.

Osaka University

Rusk Intellectual Reserve Ag

Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyuio

Kabushiki Kaisha Ueno Seiyaku Kenkyujo

K.k. Ueno Seiyaku Oyo

Sucampo Pharmaceuticals, Inc.

North Carolina State University

Ryuji Ueno

Ryuzo Ueno

Tomio Oda

Ichie Kato

Wataru Akahata

Ryu Hirata

Hiroyoshi Osama

Sachiko Kuno

Yasuhiro Harada

Tatsuya Matsukawa

Tsuyoshi Habe

Kazuhiro Masuzaki

John Cuppoletti

Akihiko Tabata

Yukiko Hashitera

Osamu Hayaishi

Yukihiko Mashima

Junichi Kawasaki

Myra L Patchen

Yoshie Nishimura

Robert Gurny

Michael Möller

Shunsuke Fukuya

Jonathan F Smith

Hiroshi Kita

Yoshihisa Oguchi

Noriyuki Yamamoto

Hiroyuki Kotajima

Takashi Hironaka

Michiharu Handa

Tohru Hirato

Yoshiki Hiida

Tomihiko Tanino

Peter Lichtlen

Makoto Suematsu

Takashi Sekida

Misako Nakata

Sachiko Tsukita

Katsuya Sakata

Adam J Moeser

Anthony T Blikslager

Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.

Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains

Provided is an alphavirus replicon particle (ARP), which comprises (i) alphavirus structural proteins comprising capsid and/or envelope, and (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nap4 and at least one gene of interest wherein at least one of capsid, and E3 and E2 in the envelope comprise one or more amino acid alteration but E1 in the envelope comprises no amino acid alteration.

Alphavirus replicon particle

The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.

Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein

Provided is a method for treating a condition or disease which is one of the indications for opioid use, which comprises administering a combination of: to a patient in need thereof.

Pharmaceutical combination of opioid and prostaglandin compound

The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.

Virus like particle comprising PD-1 antigen or PD-1 ligand antigen

A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.

Virus like particle comprising modified envelope protein E3

Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.

Method and composition for modulating immune response

Provided is a virus like particle comprising one or more flavivirus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of flavivirus infection. The flavivirus structural protein contains at least one amino acid alteration in the envelope region. Examples of flavivirus contains dengue virus.

Flavivirus virus like particle

The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections.

Malaria vaccine

Provided is a pharmaceutical composition including an 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.

Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Virus like particle composition

A method for manufacturing a fatty acid derivative represented by formula (I) is provided: wherein Zis wherein R3 is a protecting group for a hydroxy group;which includes the step of reacting a compound of formula (II): wherein Zis the same as Zexcept for when Zis Zis with a co-oxidizer under the presence of an azaadamantane-N-oxyl derivative.

Method for preparing a fatty acid derivative

Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.

Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor

Growing community of inventors

Potomac, MD, United States of America

Ryuji Ueno